Today, millions of women are surviving breast cancer. It is a malignant tumor that starts in the cells of the breast.聽It聽can grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body. No one exactly knows why some women get breast cancer; there are a...
Human breast cancer can be divided into a group that contains specific receptor sites for estrogen and a group without such specific estrogen-binding sites. The presence of specific estrogen receptors in some tumors indicating hormonal dependency has been shown to be of predictive value for endocrine...
Tamoxifen therapy has managed to reduce the chances of a breast cancer survivor developing the cancer again by 50%. However, this anti-estrogen medication does not always bring down estrogen levels enough. Rock explained in a telephone interview with Reuters that a patient cannot just assume that...
We assess the issue in clinically relevant settings by a genetic approach and inject ER + breast cancer cell lines and patient-derived tumor cells to the milk ducts of immunocompromised mice. Such ER + xenografts were exposed to physiologically relevant levels of 17-β-estradiol (E2) ...
34. ER and HER2 are mediators of two key pathways implicated in the pathogenesis of breast cancer39. Bi-directional signaling, or crosstalk, between the ER and epidermal growth factor receptor (EGFR)/HER2 signaling pathways, summarized in Fig.1, has been implicated in tumor growth and survival...
Methods. A total of 647 patients with operable stage II or III breast cancer were enrolled in two consecutive adjuvant therapy protocols conducted between 1980 and 1986. The correlations between ER status and time to first recurrence, site of first recurrence, and time to breast cancer death wer...
An anti-estrogen drug has shown a "promising" 65-percent reduction of breast cancer risk among post-menopausal women, according to the findings of a study released Saturday. The research could lead to a breakthrough for women who are at increased risk of developingbreast cancer, which strikes ...
Breast cancer, stem/progenitor cells and the estrogen receptor Dontu G,El-Ashry D,Wicha MS.Breast cancer,stem/progenitor cells and the estrogen receptor[J].Trends Endocrinol Metab,2004,15(5):193-197... Gabriela,Dontu,and,... - 《Trends in Endocrinology & Metabolism》 被引量: 643发表: ...
transformed epithelial cell nucleus. Over the last 40 years, it has been appreciated that additional cellular ER pools exist, in cytoplasm and at the plasma membrane. In this review, we discuss the important functions of extra-nuclear ER in breast cancer, including integration of function with ...
目的:探讨雌激素饥饿对肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导乳腺癌细胞MCF-7凋亡的影响及作用机制。〖HTH〗方法〖HTSS〗:MCF-7细胞培养贴壁之后,用雌激素饥饿处理后加入TRAIL,用荧光染料Hoechst染色法检测细胞的凋亡,用细胞计数法检测细胞的存活。在雌激素饥饿处理MCF-7细胞后,收集对照和饥饿组蛋白用Western blot法...